Study aim: Determining the effectiveness of oral allicin tablets on minor recurrent aphthous stomatitis Design: Controlled clinical trial, with parallel groups, unblinded, randomized, phase 3 on 60 patients. Randomization with random allocation software 2 Settings and conduct: Touba Dental Clinic, Mazandaran University of Medical Sciences Intervention method: In the intervention group (with oral allicin tablets) and control (placebo): 4 tablets (every 6 hours) daily (In addition to the examination on the day of referral), the patient must return on the third, seventh, and tenth days to assess the pain level with a visual analog scale, the size of the wound with a probe, and the length of the healing period. In this study, due to the garlic smell of the allicin-containing tablets, blinding will not be performed and the tablets will be provided to the patients after randomization. Participants/Inclusion and exclusion criteria: Inclusion criteria: Men and women aged 18 to 50 years; patients with aphthous lesions on the lips, buccal mucosa, floor of the mouth and tongue; maximum 48 hours have passed since the lesion formation. Exclusion criteria: Allergy to allicin; pregnancy or lactation; ulcer as a manifestation of a systemic disease such as Behçet's disease, ulcerative colitis, Crohn's disease or acquired immunodeficiency; use of non-steroidal anti-inflammatory drugs, narcotics, immunomodulating agents; systemic antibiotics use in the 2 weeks prior to study entry; the patient has a bleeding disorder Intervention groups: The intervention group will receive oral allicin tablets (400 mg, Dineh, Iran) containing 1100 micrograms of allicin, and the control group will receive placebo. The patient will take 4 allicin tablets (every 6 hours) (4.4 mg daily) for 10 days. Main outcome variables: Pain level; Ulcer size; Healing period